Ureteral Stent Placement

Indications for Ureteral Stenting After Lithotripsy

Extracorporeal shock wave lithotripsy (ESWL) and ureteroscopic laser lithotripsy (URS) fragment kidney and ureteral stones, but the fragmented ureter is left swollen, irritated, and sometimes injured. A double-J (JJ) stent is placed to guarantee unobstructed urine drainage from the kidney to the bladder while the ureter recovers — preventing the single most dangerous post-procedure complication: obstructed, infected urine (obstructive pyonephrosis).

• 60–80%: Post-URS stenting rate (of ureteroscopic stone cases)
• 3–5%: Ureteral perforation risk (during URS lithotripsy)
• 4–7%: Steinstrasse after ESWL (fragment "column" obstruction)
• +10–15%: Stone-free rate boost (with routine stenting after URS)

Why the post-lithotripsy ureter needs protection

Laser and shock-wave lithotripsy pulverize stones into fragments that must still pass down the ureter, and the instrumentation itself traumatizes the urothelium. Within hours, the ureteral wall becomes edematous — its normally 2–3 mm lumen can narrow to a pinhole. Combined with residual fragment debris, this creates a high risk of acute obstruction.

A JJ stent bypasses this narrowed, inflamed segment entirely: urine drains around and through the stent regardless of how swollen the surrounding wall becomes, converting a potential surgical emergency into a routine, self-resolving recovery.

An obstructed, infected kidney (obstructive pyonephrosis) is a urologic emergency — untreated, urosepsis mortality can exceed 20–40%. Decompression (stent or percutaneous nephrostomy) is required within hours, not days, once fever and obstruction coexist.

Steinstrasse and residual fragment burden

"Steinstrasse" (German: "stone street") describes a column of stone fragments impacted sequentially down the ureter after ESWL, most often below a large proximal stone burden (>15–20 mm). It occurs in roughly 4–7% of ESWL cases and is a classic indication for pre-emptive or reactive stenting.

Other fragment-related indications: • Large stone burden (>1.5–2 cm) fragmented in a single session — high fragment volume • Solitary or transplant kidney — any obstruction risks the only functioning renal unit • Bilateral simultaneous procedures — obstruction of both units is catastrophic • Pre-existing hydronephrosis or impaired renal function

Iatrogenic injury and patient-selection indications

Direct ureteroscopic injury is stented essentially universally:

• Ureteral mucosal abrasion / false passage — stent splints the injury and prevents stricture • Ureteral perforation (3–5% of URS cases) — stent diverts urine away from the perforation to allow sealing • Impacted or long-duration procedures with prolonged instrumentation and edema • Pregnancy — physiologic ureteral compression plus stone disease often mandates stenting over repeat imaging-guided intervention • Anticipated difficult stone passage — stent as a "safety net" avoiding an ER return visit for colic

Not every lithotripsy patient needs a stent: small stone burden, short operative time, and an atraumatic procedure in a normal ureter increasingly favor a stent-free approach, since every stent carries its own symptom burden.

Cystoscopic Placement Technique — Guidewire, Fluoroscopy, Coil Formation

Double-J stents are placed retrograde through a cystoscope, almost always under fluoroscopic guidance, immediately following the primary lithotripsy procedure. The technique is fast (typically adding 5–10 minutes) but precision matters: a malpositioned coil can cause pain, reflux, or failure to drain.

• 0.035–0.038": Guidewire diameter (hydrophilic or PTFE-coated)
• 22–30 cm: Stent length range (chosen by patient height)
• 4.7–7 Fr: Stent diameter (French) (6 Fr most common in adults)
• 5–10 min: Added procedure time (appended to primary lithotripsy)

Step-by-step retrograde technique

1. Cystoscope (rigid or flexible) is passed into the bladder; the ureteral orifice is identified and cannulated. 2. An open-ended ureteral catheter is advanced over a floppy-tipped guidewire (0.035–0.038") up the ureter, past the stone/fragment field, into the renal pelvis — confirmed under fluoroscopy. 3. The catheter is withdrawn, leaving the wire in place as a rail. 4. The double-J stent, preloaded on a pusher/positioner, is advanced over the wire until its proximal end and radiopaque marker reach the renal pelvis. 5. The pusher advances the stent while the guidewire is simultaneously withdrawn — this releases stored elastic memory in the stent tip, curling it into the proximal (renal) pigtail coil. 6. The wire is withdrawn further and the distal end is released into the bladder, curling into the distal (bladder) pigtail coil under cystoscopic direct vision.

Correct coil position is confirmed by two independent checks: fluoroscopic imaging (both coils curled, stent not looped or kinked in the ureter) and direct cystoscopic visualization of the bladder coil forming normally, not left extending up into the ureter.

Fluoroscopic confirmation and malposition pitfalls

Fluoroscopy is used throughout to track the guidewire tip location, confirm the stent has not buckled within the ureter ("stent looping"), and verify final coil position before the cystoscope is withdrawn.

Common malpositions and consequences: • Proximal coil too low (mid-ureter) — inadequate renal drainage, may still obstruct • Distal coil retained in the ureter, not the bladder — severe irritative symptoms, poor drainage, risk of migration upward • Stent too short — distal coil pulled up out of the bladder by ureteral peristalsis and respiration-driven kidney motion • Stent too long — excess distal coil bulges against the trigone, causing marked bladder irritative symptoms

A post-procedure plain abdominal film (KUB) is often obtained to document baseline coil position for comparison at follow-up.

Sizing selection — length and diameter

Diameter (French, Fr; 1 Fr = 0.33 mm) is chosen by ureteral caliber and expected drainage need — narrower stents (4.7–6 Fr) are more comfortable and are the default in most uncomplicated cases; wider stents (7 Fr) offer a larger lumen for high-output drainage or heavily encrusted/obstructed systems.

Length is chosen from the patient's height, since the ureter runs a fairly predictable distance from renal pelvis to bladder trigone. An incorrectly sized stent is one of the most common causes of severe stent-related symptoms.

Typical adult stent length by patient height

In-Situ Stent Function — Dual-Pathway Drainage & Peristalsis

A correctly positioned double-J stent does not pump urine — it is a purely passive conduit. Drainage occurs through two parallel pathways simultaneously: a central intraluminal channel and, more importantly at typical urine flow rates, the extraluminal capillary space between the stent's outer wall and the surrounding ureteral mucosa. Understanding this dual mechanism explains both why stents work and why they disrupt the ureter's normal one-way valve.

• 24–50: Side holes per stent (along the shaft, both coils)
• Extraluminal: Dominant flow pathway (at normal urine output)
• ~1.0–1.7 mm: Typical lumen inner diameter (for a 6–7 Fr stent)
• Polyurethane / silicone: Common materials (± hydrophilic coating)

Two simultaneous drainage pathways

Intraluminal flow: urine enters the proximal coil's side holes and open tip, travels down the central 1.0–1.7 mm lumen, and exits through distal side holes and the open bladder end. This pathway dominates only during high urine flow states (e.g., diuresis, IV fluids).

Extraluminal flow: at typical resting urine production, most drainage actually occurs in the narrow capillary-like space between the outer stent surface and the folded ureteral urothelium — driven by the mucosal folds acting as tiny channels alongside the stent, assisted by residual peristaltic milking of the ureteral wall. This is why an indwelling stent can still drain effectively even if its lumen becomes partially obstructed by debris or encrustation.

Because most urine bypasses the stent lumen extraluminally, a stent can continue draining adequately even with meaningful intraluminal debris — but this also means encrustation can progress silently before flow is compromised enough to cause symptoms.

Material properties and biocompatibility

Polyurethane: stiffer, offers good pushability during insertion and resists external compression, but is somewhat more prone to encrustation and mildly more irritating to the bladder trigone than silicone.

Silicone: softer and more biocompatible with lower encrustation and biofilm adherence rates, favored for longer planned dwell times — but its greater flexibility makes it harder to push into place, sometimes requiring a stiffer inserter.

Newer copolymers (C-Flex, Percuflex, hydrogel/hydrophilic-coated stents) attempt to combine push characteristics with reduced encrustation; hydrophilic coatings absorb water to create a slippery, less bio-adherent surface that reduces friction on both insertion and removal.

Loss of the ureterovesical valve — the anti-reflux trade-off

The normal ureterovesical junction (UVJ) is a one-way valve: the oblique, submucosal tunnel of ureter through the bladder wall collapses shut during bladder filling and voiding, preventing urine from refluxing back up toward the kidney.

A JJ stent physically props this tunnel open for its entire dwell time, abolishing the valve mechanism. During voiding, rising bladder pressure is transmitted directly up the stent lumen to the renal pelvis — vesicoureteral reflux. This single mechanism explains the classic stent symptom of flank/kidney pain specifically during or immediately after voiding.

Stent material comparison

Stent-Related Symptoms, Biofilm Formation & Encrustation Risk

The double-J stent is remarkably effective at preventing obstruction, but it is a permanent foreign body bathed in urine — and the vast majority of patients feel it. Irritative voiding symptoms, biofilm colonization, and mineral encrustation are the predictable price of an indwelling stent, and all three worsen the longer the stent remains in place.

• ~80%: USSQ symptom prevalence (report ≥1 bothersome symptom)
• ~27%: Encrustation, <6 weeks dwell (of retrieved stents)
• ~76%: Encrustation, >12 weeks dwell (of retrieved stents)
• Within days–weeks: Biofilm colonization (nearly universal by 4–6 wk)

Irritative lower urinary tract & flank symptoms

The Ureteral Stent Symptom Questionnaire (USSQ), the validated instrument for this problem, finds that roughly 80% of stented patients report at least one bothersome symptom, most commonly:

• Urinary frequency and urgency — the bladder-coil tip mechanically irritates the trigone, the most sensation-dense area of the bladder • Dysuria and suprapubic pain — direct mucosal irritation • Hematuria — mucosal friction against the coil, worse with activity • Flank/kidney pain during or just after voiding — vesicoureteral reflux transmitting bladder pressure up to the renal pelvis (see Stage 3) • Reduced work productivity and sleep disturbance — USSQ studies consistently show measurable quality-of-life impact, often underappreciated clinically

Stent symptoms are frequently underestimated by clinicians relative to patients' actual experience — USSQ studies show a majority of stented patients rate symptoms as moderate-to-severe, yet stents are often framed to patients as a minor, symptom-free step of recovery.

Biofilm formation and bacterial colonization

Any indwelling urinary polymer surface begins acquiring a conditioning film of host proteins (Tamm-Horsfall protein, albumin) within hours of placement. Bacteria adherent to this film secrete an extracellular polysaccharide matrix, forming a mature biofilm that is markedly more resistant to antibiotics and host immune clearance than free-floating (planktonic) bacteria of the same species.

Colonization becomes essentially universal the longer a stent dwells — by 4–6 weeks the large majority of retrieved stents culture positive, even in asymptomatic patients. Common organisms include E. coli, Enterococcus, Klebsiella, Proteus, and Pseudomonas. Biofilm-associated bacteria are the reservoir for stent-associated urinary tract infection and, in urease-producing organisms (Proteus, some Klebsiella), directly drive infection-related (struvite) encrustation.

Encrustation and stone formation on the stent surface

Encrustation is the deposition of calcium oxalate, calcium phosphate, or (with urease-producing bacteria) struvite crystals onto the biofilm-coated stent surface. Risk factors include prolonged dwell time, metabolic stone disease, recurrent UTI, dehydration, and pre-existing hyperuricosuria/hypercalciuria.

Dwell time is the single strongest predictor. Classic series correlating encrustation with indwelling duration found roughly: • <6 weeks: ~27% of stents show any encrustation • 6–12 weeks: ~57% • >12 weeks: ~76%, with heavy, stone-like encrustation becoming common

Severe encrustation can fuse the coils to the ureteral or renal pelvic wall, fragment the stent, or generate secondary stones requiring their own separate lithotripsy — turning a simple office removal into a major endourologic procedure.

Encrustation risk by indwelling (dwell) time

Stent Removal & Outcomes

A ureteral stent is always meant to be temporary. Removing it at the right time, by the right technique, closes the loop on lithotripsy recovery — restoring normal ureteral valve function and eliminating the ongoing symptom and encrustation burden. The single most important predictor of a good outcome is simply that the stent actually gets removed on schedule.

• 5–14 days: Typical removal timing (uncomplicated post-lithotripsy)
• 4–6 weeks: Extended dwell (injury/edema) (ureteral perforation cases)
• ~5 min: Cystoscopic grasp procedure (office-based, local anesthesia)
• Not rare: "Forgotten stent" reports (leading cause: lost follow-up)

Removal timing and technique

Uncomplicated post-lithotripsy stents are typically removed at 5–14 days, once the acute post-procedure edema has resolved and any residual fragments have had time to pass. Stents placed for ureteral injury or perforation are left longer, commonly 4–6 weeks, to allow full mucosal healing.

Two removal techniques are used:

1. Cystoscopic grasp — a flexible or rigid cystoscope is passed into the bladder, grasping forceps are used to grip the distal pigtail coil, and the entire stent is withdrawn under direct vision as the coil straightens against the guiding sheath. Quick, office-based, local anesthesia.

2. Extraction string — a fine suture is left attached to the distal end of the stent at insertion, exiting through the urethra and taped externally. The patient (or clinic staff) simply pulls the string to remove the stent at the scheduled time, without any repeat cystoscopy.

Consequences of prolonged or forgotten retention

Every week a stent remains beyond its intended removal date increases encrustation, biofilm burden, and symptom load (Stage 4). Beyond a certain point, retained stents can cause:

• Progressive encrustation and secondary stone formation on the coils • Stent fragmentation, with pieces migrating or becoming embedded in the ureteral wall • Recurrent or breakthrough urinary tract infection / pyelonephritis from the colonized biofilm • Ureteral obstruction if encrustation or tissue ingrowth blocks flow • Loss of renal function in severe, prolonged, unrecognized obstruction

"Forgotten stent syndrome" — a stent left in place well beyond its planned duration because of lost follow-up — remains a recognized and preventable cause of major morbidity, sometimes requiring combined percutaneous nephrolithotomy (PCNL), ureteroscopy, and cystolitholapaxy to clear a single, heavily encrusted stent.

The single most effective safeguard against a forgotten stent is a structured tracking system — a written removal date given to the patient, an automated recall/reminder, or a registry flag — rather than relying on patient memory alone.

Expected outcomes and follow-up

After timely stent removal, the ureterovesical valve mechanism recovers promptly and irritative symptoms typically resolve within 24–48 hours; mild hematuria for a few days is common and expected. Follow-up imaging (ultrasound or low-dose CT) is often obtained at 4–6 weeks to confirm resolved hydronephrosis, stone-free status, and normal ureteral caliber.

With appropriately timed placement and removal, double-J stenting after lithotripsy has an excellent track record: obstruction and urosepsis are effectively prevented, and the transient symptom burden resolves completely once the stent is out — making it, despite its discomforts, one of the most reliable safety measures in modern stone surgery.

Removal method comparison